The chances of a swift approval for tarlatamab, one of the jewels in Amgen, Inc.'s oncology crown, for small-cell lung cancer have received a major boost following promising and potentially registrational data presented at the European Society for Medical Oncology (ESMO) congress in Madrid.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?